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Defects of complex I are involved in many human mitochondrial diseases, and therefore we have proposed to use the NDI1 gene encoding a
single subunit NADH dehydrogenase of Saccharomyces cerevisiae for repair of respiratory activity. The yeast NDI1 gene was successfully
introduced into mammalian cell lines. The expressed NDI1 protein was correctly targeted to the matrix side of the inner mitochondrial membranes,
was fully functional and restored the NADH oxidase activity to the complex I-deficient cells. The NDI1-transduced cells were more resistant to
complex I inhibitors and diminished production of reactive oxygen species induced by rotenone. It was further shown that the NDI1 protein can be
functionally expressed in tissues such as skeletal muscles and the brain of rodents, which scarcely induced an inflammatory response. The use of
NDI1 as a potential molecular therapy for complex I-deficient diseases is briefly discussed, including the proposed animal model.
© 2006 Elsevier B.V. All rights reserved.Keywords: NADH dehydrogenase; Complex I; Gene therapy; Mitochondrial disease; Parkinson's disease; Adeno-associated virus1. NADH dehydrogenases of the respiratory chains
The NADH dehydrogenases (NADH-quinone oxidoreduc-
tases) of the respiratory chain catalyze electron transfer from
NADH to quinone. In other words, the NADH dehydrogenases
are the point of entry for the major fractions of electrons that
traverse the respiratory chains. In addition to this function, the
enzymes in many bacteria and mitochondria translocate H+ and/
or Na+ across the membranes [1]. The NADH dehydrogenases
can be divided into at least three groups [2,3]. These are the H+-
translocating NADH dehydrogenase (complex I and NDH-1,
respectively, for mitochondrial and bacterial enzymes), the
NADH dehydrogenase lacking an energy-transduction (NDH-
2), and the Na+-translocating NADH dehydrogenase (Na+-
NDH or Na+-NQR) [3,4]. Table 1 compares the characteristics
of complex I/NDH-1 and NDH-2. Complex I/NDH-1 and
NDH-2 type enzymes are present in both bacteria and
mitochondria, whereas in animal mitochondria, complex I is
the sole NADH dehydrogenase [1,5,6].⁎ Corresponding authors. Fax: +1 858 784 2054.
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NDH-2 has been detected in archaea, bacteria, and fungal
and plant mitochondria but not in mammalian mitochondria [3]
and is generally composed of a single polypeptide whose
molecular size is approximately 50 kDa. NDH-2 bears one FAD
as a cofactor and no iron–sulfur clusters, in contrast to complex
I/NDH-1. The exception being, NDH-2, isolated from Trypa-
nosoma brucei mitochondria [7] and Sulfolobus metallicus [8]
have been reported to house FMN instead of FAD. In addition,
NDH-2 appears to contain at least one quinone [9]. According
to a recent review [10], NDH-2 can be divided into at least three
groups on the basis of its primary structure properties,
designated NDH-2A, -2B, and -2C. NDH-2A contains two
nucleotide-binding motifs and is located in a wide range of
organisms from bacteria to mitochondria. NDH-2B houses the
Ca2+-binding motif (EF motif) in addition to two nucleotide-
binding motifs and is known to be present in certain
mitochondria. NDH-2C bears only one nucleotide-binding
motif and is mainly present in archaea.
Baker's yeast, Saccharomyces cerevisiae mitochondria lacks
a complex I-type enzyme but contain two types of NDH-2. Both
types of NDH-2 are associated with the inner mitochondrial
Table 1
Characteristics of Complex I/NDH-1 and NDH-2
Complex I/NDH-1 NDH-2
Ion-pump H+ (and Na+?) not a pump
ROS generation Yes Yes or No












Organisms Animal mitochondria Plant mitochondria
Plant mitochondria Fungal mitochondria
Fungal mitochondria Bacteria
Bacteria Archaea
a As described in the text, NDH-2 isolated from T. brucei mitochondria [7]
and S. metallicus [8] was reported to house FMN.
b Although some inhibitors for NDH-2 have been reported at the present time
[1,59], inhibitors specific to NDH-2 are not available.
Table 2
Diseases caused by complex I defects
Mitochondrial DNA modification
Leber's hereditary optic neuropathy (LHON)
Lactic acidosis and stroke-like episodes (MELAS)
Myoclonus epilepsy with ragged red fibers (MERRF)
Leigh syndrome
Progressive epilepsy, stroke-like episodes, optic atrophy and cognitive decline
Nuclear DNA modification
Leigh syndrome
Hypertropic cardiomyopathy and encephalomyopathy
Hypoglycemia and lactic academia
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faces the inner membrane space, designated external NADH
dehydrogenases, Nde1 and Nde2, and the other is on the matrix
side of the inner mitochondrial membrane, designated internal
NADH dehydrogenase, NDI1. It has been reported that Nde1
and/or Nde2, but not NDI1, generate superoxide radicals
coupled to NADH oxidation [11]. Native expression of the
yeast mature NDI1 in E. coli is successful and characterization
of this enzyme is in progress (unpublished data).
3. Characteristics of complex I/NDH-1
As described in Table 1, complex I and NDH-1 are
composed of 46 and 13–14 different subunits, respectively
[12]. As far as our present knowledge is concerned, complex I
has the most intricate structure of the membrane-associated
enzyme complexes. It is known that complex I/NDH-1 have an
L-shaped structures and are composed of two arms [13]. One is
the peripheral arm which protrudes into the mitochondrial
matrix/bacterial cytoplasmic compartment [14], while the other
is the membrane arm, most of which is embedded in the inner
mitochondrial/bacterial membranes. There are seven subunits of
complex I (designated ND1–6 and 4L) which are encoded by
mitochondrial DNA (mtDNA) [15,16]. In NDH-1, the homo-
logues of ND1–6 and 4L subunits construct the membrane
segment [17–20]. Complex I/NDH-1 contain one non-cova-
lently bound FMN and 8–9 iron–sulfur clusters as prosthetic
groups [6,21]. There are two [2Fe–2S] centers (N1a and N1b)
and 6–7 [4Fe–4S] centers (N2, N3, N4, N5, N6A, N6B and
additional N7 in certain bacteria) [21–23]. Of these, centers
N1a, N1b, N2, N3, N4, and partially N5 have been reported to
be EPR-detectable [21]. All cofactors of complex I/NDH-1 are
located in the peripheral segment [13]. In addition, Sazanov's
group recently determined the location of 9 iron–sulfur clustersfrom Thermus thermophilus HB-8 NDH-1 by X-ray crystallo-
graphic analyses of the peripheral segment [24]. Complex I/
NDH-1 have specific inhibitors such as rotenone, piericidin A,
capsaicin, pyridaben and acetogenins although rotenone not
effective for E. coliNDH-1. These inhibitors are thought to bind
to the inhibitor-binding pocket which is constructed by 49k,
PSST, ND1, ND4, and ND5 subunits [25–30]. Complex I [31]
and possibly NDH-1 [32] are considered to be one of the major
sites for production of reactive oxygen species (ROS) along
with complex III.
4. Strategy for overcoming complex I deficiencies
Recently, it has been reported that structural and functional
defects of complex I are involved in many human mitochondrial
diseases (Table 2) [33]. In addition, it has been hypothesized
that complex I may play a role in cases of sporadic Parkinson's
disease [34,35]. However, various chemotherapies employed to
treat these diseases have been reported to be only moderately
effective [36]. Presently, mutations and deletions of the
mtDNA-encoded subunits are not repairable although various
attempts have been made [37]. Replacing a mutated subunit
with a wildtype subunit introduced through gene delivery met
some success [38,39]. However, there are a number of issues to
overcome. For example, it is necessary to achieve highly
efficient and controlled expression of the transgene, proper
integration of the expressed subunit, and displacement of the
defective subunit. Therefore, it is important to explore new
strategies that would restore the NADH oxidase activity
irrespective of the cause of complex I deficiencies. In this
article, we introduce our unique strategy to restore the
mitochondrial respiratory activity.
As described above, in mammalian mitochondria, complex I
is the only NADH-Q oxidoreductase in the respiratory chain.
In the S. cerevisiae mitochondria, the NDI1 enzyme catalyzes
electron transfer from NADH to Q in the matrix compartment
and is the main entry point into the respiratory chain, just as in
complex I. We showed in earlier work that the mature NDI1
enzyme, expressed in E. coli, was able to perform as a member
of the respiratory chain in prokaryotic host cells [40]. In
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in bacteria as well as plant and fungal mitochondria [41]. This
fact suggests that neither the association of the NDI1 type
enzyme with the inner mitochondrial membranes nor its
function will be negated or hindered by the presence of
endogenous complex I. Based on this knowledge, we
postulated that one approach to coping with complex I defects
may be to introduce an NDI1-type enzyme into mammalian
mitochondria. When this project was planned, the only
available DNA sequence of the NDI1 gene was from S.
cerevisiae [42,43]. The yeast NDI1 gene is composed of
1539 bp which is predicted to encode a precursor polypeptide
of 513 amino acid residues. Of these amino acid residues, the
first 26 residues of N-terminal serve as the signal sequence for
import into mitochondria. Therefore, we attempted to use the
yeast NDI1 gene to repair complex I defects. As a first step, the
attempt was made to functionally express the NDI1 gene in
cultured mammalian cells.
5. Expression of the NDI1 enzyme in proliferating cells
We have thus far successfully expressed the NDI1 enzyme
in 10 cell lines [44–49], of which two were complex I-
deficient. One had a defect in the nuclear DNA-encoded
MWFE subunit (Chinese hamster CCL16-B2) and the other
lacked the mtDNA-encoded ND4 subunit (C4T), the
remainder were normal cell lines: human osteosarcoma
143B (C4T parent), human embryonal kidney 293 (HEK
293), mouse mesencephalic neuronal cell (MN9D), rat adrenalFig. 1. The Ndi1 expression in various cultured cells. A, Chinese hamster CCL16B2;
immunostained using the antibody against the yeast Ndi1. In rat PC12 cells, both cepheochromocytoma cells (PC12), human fibroblast cells, and
human neuroblastoma cells (SK-N-MC). In all cells tested,
the NDI1 was expressed in the cytoplasmic phase (see Fig. 1).
In the case of dopamine-producing PC12 and MN9D cells,
the NDI1 enzyme was also expressed in neurites (Fig. 1), and
confocal images revealed that the expressed NDI1 was located
predominantly in the mitochondria [48]. It was evident that
the NDI1 leader sequence successfully directed the enzyme to
the mitochondria in host cells. Furthermore, the expressed
NDI1 enzyme was able to restore the NADH oxidase activity
in the complex I-deficient mutant cell lines (Fig. 2). The
restored activity was ascribed to the presence of the NDI1
enzyme because the activity was insensitive to rotenone, a
specific complex I inhibitor, but was sensitive to flavone, an
inhibitor of the yeast NDI1 enzyme (Fig. 2). In the NDI1-
transduced normal cells, the immunochemical analyses
suggest that the expressed NDI1 enzyme does not displace
the endogenous complex I, but works in parallel [45]. The
NADH oxidase activity of the NDI1-transduced HEK293 and
143B cells was not affected by rotenone [45,47]. The P/O
ratios coupled to NADH oxidation were lowered from 2.4 to
1.8 by NDI1-transfection while the P/O ratios coupled to
succinate oxidation (1.6) were not changed, indicating that
coupling site 1, but not coupling sites 2 and 3, was lost. The
NDI1-transduced cells can grow in the culture medium
containing complex I specific inhibitors such as rotenone
and 1-methyl-4-phenylpyridium ion whereas non-transduced
cells cannot survive in the same media. It was concluded that
the yeast NDI1 enzyme can be functionally expressed inB, human 143B; C, mouse MN9D; D, human fibroblast; E, rat PC12. Cells were
ll bodies and neurites contain the Ndi1 protein.
Fig. 2. Recovery of the NADH oxidase activity of complex I-deficient Chinese
hamster CCL16-B2 mutant cells using the Ndi1 protein. A, non-transducing
mutant cells; B, NDI1-transducing cells. Where indicated, 5 mM glutamate
(Gul), 5 mM malate (Mal), 5 μM rotenone (rot), 5 mM succinate (succ), 5 μM
antimycin A (AntA), and 0.5 mM flavone were added. For oxygraph assays,
digitonin-permeabilized cell systems were used.
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chain in host cells.
6. Reduced production of ROS in the NDI1-transduced
cells
Most of the electrons, which are donated to the mammalian
mitochondrial respiratory chain, migrate along the respiratory
chain to finally reach cytochrome c oxidase where they safely
combine with oxygen and protons to form water [50]. However,
at several upstream sites of the respiratory chain (complexes I
and III and ubiquinone), a fraction of these electrons can directly
react with oxygen, to form the superoxide anion radicals. Most
of the radicals are then dismutated by mitochondrial superoxide
dismutase into H2O2, which is detoxified into water by
mitochondrial glutathione peroxidase [51]. It is believed that
oxidative stress is a major cause of senescence and many age-
related diseases. In fact, a recent article reported that expression
of catalase into mitochondria extends the mouse lifespan [52]. It
is also hypothesized that defects of complexes I and/or III
generate reactive oxygen species (ROS) which causes oxidative
stress. Therefore, NDI1 is expected to decrease ROS generation
caused by complex I defects, and our preliminary results suggest
that NDI1 expression helped reduce ROS generation induced by
rotenone, a complex I inhibitor.
7. Expression of the NDI1 enzyme in non-proliferating cells
Mitochondrial defects often occur in non-proliferating or
slowly proliferating tissues. Therefore, successful therapy willrequire that the NDI1 gene can be functionally expressed in
differentiated and non-dividing cells. For this purpose, we
constructed NDI1-recombinant adeno-associated virus (rAAV-
NDI1) in collaboration with Dr. Flotte (University of Florida).
First, we used the rAAV-NDI1 particles for expression of the
NDI1 gene in growth-arrested human cells [46]. The NDI1 gene
was successfully introduced into non-proliferating human 143B
and HEK293 cells using rAAV-NDI1, and the NDI1-infected
cells can survive in media containing rotenone. The NDI1
protein expressed in non-proliferating cells was shown to be
functionally active, as was seen in proliferating cells. Further-
more, when cells were cultured under the conditions where
energy has to be provided by respiration, the NDI1-transduced
cells were able to grow even in the presence of added complex I
inhibitor such as rotenone and 1-methyl-4-phenylpyridinium
ion. In contrast, control cells that did not receive the NDI1 gene
failed to survive as anticipated. Based on these positive results,
it is highly likely that the viral gene delivery method can be
extended to in vivo experiments.
8. In vivo expression of the NDI1 enzyme
Our earlier experiments showed that the NDI1 enzyme can
replace or supplement the functionality of complex I in various
cultured cells. For this approach to be useful, it is important to
demonstrate in vivo that the mature protein is correctly placed in
the mitochondria. To assess the feasibility of rAAV-NDI1 as a
gene delivery method in vivo, we carried out injections of the
viral particles into tissues in rats and mice [53]. First, the rAAV-
NDI1 vector was injected intomouse skeletal muscles. TheNDI1
enzyme was detected as early as 1 week after injection by
immunohistochemistry using the antibody against NDI1. The
area ofNDI1 expression increasedwith time and reached a steady
level approximately 4 months post-injection, and the level of
expression remained unchanged even after 7 months. Some
muscle cells appeared to expressNDI1more than others, which is
most likely a result of the difference between the type I (rich in
mitochondria) and type II (mitochondria poor) fibers. A similar
pattern ofNDI1 expressionwas observed for rat skeletalmuscles.
Next, we injected rAAV-NDI1 stereotaxically into the
substantia nigra (SN) of rats and mice unilaterally. In mice,
expression of the NDI1 protein was observed near the injection
site approximately 2 weeks after the injection and lasted for at
least 7 months. The rat SN was examined between 7 weeks and 4
months post-injection, which showed a sustained level of NDI1
expression. The immunostaining analyses showed strong trans-
duction of dopaminergic neurons in the substantia nigra pars
compacta (SNc) (Fig. 3). NDI1 was also detected in the striatum
of the ipsilateral side, indicating theNDI1 protein expressed in the
SNc was transported anterogradely to the terminals of the
dopaminergic neurons. In addition, we carried out stereotaxic
injections of rAAV-NDI1 into rat and mouse striatum. Approx-
imately 2 weeks after injection in the rat striatum, the NDI1
protein was observed in the area around the site of injection.
Similar expression was observed in the mouse striatum.
To investigate whether the NDI1 is also guided to mitochon-
dria in vivo, we double-stained the tissues using the anti-NDI1
Fig. 3. Expression of Ndi1 in substantia nigra in rats. Top panel, immunostaining by the antibody directed to the Ndi1 protein. Four panels, confocal images of the
framed area in the top panel using anti-Ndi1 antibody (green), anti-F1-ATPase subunit α antibody as a mitochondrial marker (red), and To-Pro3 iodide for nuclear
staining (blue).
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protein and examined the tissue by confocal microscopy. It
turned out that the expressed NDI1 was predominantly localized
to mitochondria (Fig. 3), and led us to conclude that the results of
in vivo experiments are similar to those obtained in vitro using
cultured cells. It is apparent that the leader sequence of the yeast
NDI1 protein can guide the polypeptide to mammalian
mitochondria in vivo as well as in vitro.
To assess whether the expressed NDI1 protein has NADH
dehydrogenase activity, sections of skeletal muscles, SN, and
striatum of rats and mice were subjected to an NADH
dehydrogenase activity assay [53]. The assay method involves
reduction of p-nitroblue tetrazolium with NADH caused by theNADH dehydrogenase activity and is commonly used for
assessment of complex I activity in native gels. In skeletal
muscles, there are at least two types of myofibrils; one
designated slow myofibrils, which are rich in mitochondria
and the other fast myofibrils, which have fewer mitochondria.
Therefore, patterns of the NADH dehydrogenase activity
staining in skeletal muscles are mosaic in nature. This makes
visualization of the activity ascribed to the NDI1 enzyme more
of a challenge. Nevertheless, the muscle cells expressing NDI1
seem to exhibit stronger staining of NADH dehydrogenase
activity. The activity derived from the NDI1 enzyme is much
better visualized in the striatum where the background NADH
dehydrogenase activity is very low. The neurons of the SN on
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NADH dehydrogenase activity presumably because of the
NADH dehydrogenase activity of the NDI1 enzyme. Neurons
on the opposite side had relatively low staining, which
represents the activity of endogenous complex I. The data
indicate that the NDI1 enzyme being expressed in the SN, the
striatum and skeletal muscles is functionally active.
It is known that an inflammatory response could be one of
the negative factors in gene therapy. Therefore, we have
examined sections of the NDI1-expressed SN, striatum, and
skeletal muscles using hematoxylin and eosin staining analyses.
As far as our in vivo experiments are concerned, no significant
inflammatory response was detected in the area of NDI1
expression [53], and we obtained the same negative result with
immunohistochemical staining using the antibody against CD-
8. In addition, all animals tested showed normal behavior and
no weight loss throughout the observation period. It seems
unlikely, based on the above results, that the NDI1 expression
induces harmful effects on rodent health.
9. Possible use of the NDI1 gene as a therapeutic agent for
complex I defects
In vitro experiments using cultured cells and successful
expression of NDI1 in animal tissues indicate a great possibility
that the gene is capable of compensating defective complex I in
vivo. Unfortunately, there are no established animal models for
complex I deficiency in which to test the effectiveness of NDI1.
However, it seems likely that animal models of Parkinson's
disease (PD) may be suitable for this purpose. Complex I
deficiency in the brain of a patient with PD was first described in
1989 [54]. Numerous studies have followed which indicated
involvement of complex I in early events of neurodegeneration
in sporadic PD. More recently, complex I inhibitors such as
rotenone [55,56] and acetogenins [57,58,58] were shown to
produce effects in rats that resemble human PD. We used a
mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
model of PD and carried out preliminary studies. We injected the
rAAV-NDI1 particles unilaterally into the SN of mice prior to
MPTP treatment and assessed the degree of neurodegeneration
in the nigrostriatal system by histochemical analyses for
tyrosine hydroxylase (TH) and glial fibrillary acidic protein
(GFAP). It was clearly seen that the SN neurons of the rAAV-
NDI1-injected side was retained a high level of TH-positive
cells and that the ipsilateral striatum exhibited significantly less
denervation than the contralateral side (unpublished data).
Although preliminary, the results suggest that theNDI1 gene has
protective effects against neurodegeneration caused by MPTP.
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